Injective (INJ) is currently priced at $2.83, reflecting a slight decline of 0.99% over the last 24 hours. The daily trading range has been relatively tight, with a high of $2.92 and a low of $2.82, indicating low volatility and a lack of strong buying or selling pressure.

Trading volume stands at approximately $33.86 million, which corresponds to a volume-to-market cap ratio of 11.97%. This suggests a moderate level of trading activity relative to its market capitalization, implying that while some traders are active, overall sentiment may be cautious.

Technical indicators show that the short-term moving averages (8, 13, and 21 SMA) are all in a downtrend, with declines ranging from 1.49% to 2.41%. The longer-term 144 SMA is significantly lower at $2.98, indicating that the price may be struggling to maintain upward momentum in the face of bearish pressure.

The Relative Strength Index (RSI) readings further confirm this sentiment; the 1-hour RSI is at 42, suggesting that INJ is nearing oversold territory. The 7-day RSI is at 45, and both the 7-day and 14-day price changes are negative, indicating a weakening trend over a more extended period.

Injective has also seen a notable decrease of approximately 11.49% over the past 30 days, which reflects broader bearish sentiment in the market. Additionally, the all-time high of $52.62, reached in March 2024, highlights a significant gap between the current price and previous highs, which may deter new investors.

Given the current technical indicators, declining moving averages, and bearish momentum, the market sentiment for INJ appears weak. Based on this analysis, a Sell rating is appropriate as the asset shows signs of continued downward pressure and lack of immediate bullish catalysts.